List view / Grid view
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
Scientists have discovered a powerful new antibiotic hidden within the compound pre-methylenomycin C lactone, which shows real effectiveness against drug-resistant infections such as MRSA and VRE.
New research has discovered that mixtures of everyday medications in the environment can promote antibiotic resistance, offering new insights that could influence future drug discovery and environmental policy.
Scientists have discovered a new family of bacterial proteins – called ComFB – that regulate both movement and DNA uptake – suggesting potential new methods to combat pathogenic infections.
Scientists have supercharged vinegar’s antibacterial properties by adding carbon and cobalt nanoparticles – creating a powerful, non-toxic treatment that could help combat drug-resistant infections and speed up wound healing.
Scientists at the University of Liverpool have discovered Novltex, a new class of antibiotics that shows potent activity against deadly multidrug-resistant bacteria such as MRSA.
Penn engineers have built an AI model that creates new antibiotics – and early tests show some work as well as existing approved drugs.
Japanese researchers have discovered how the bacterial proteins FtsZ and ZapA work together to drive cell division – a discovery that could guide the development of new antibacterial treatments.
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we…
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
